Tag - ContraVir

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Executive Moves

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

ContraVir Pharmaceuticals (NASDAQ:CTRV) appointed industry veteran, Robert Foster, as acting CEO, succeeding James Sapirstein.

October 3, 2018

Tag - ContraVir

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

General

More